Developing small molecules to target Alzheimer's disease proteins
TREAT AD Medicinal Chemistry Core
This study is working on developing tiny molecules that can attach to certain proteins linked to Alzheimer's disease, with the hope of finding new ways to help researchers better understand and treat the condition.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-10954116 on NIH RePORTER |
What this research studies
This research focuses on creating small molecules that can effectively bind to specific proteins associated with Alzheimer's disease. Led by Dr. Alison Axtman at Emory University, the project aims to optimize these molecules for better potency and selectivity. The approach includes advanced techniques such as DNA-encoded library screening combined with machine learning to discover potential drug candidates. The goal is to provide valuable chemical probes that can be shared with the scientific community to further investigate Alzheimer's disease.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or those at risk of developing it.
Not a fit: Patients with other forms of dementia or cognitive impairment unrelated to Alzheimer's disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic options for patients with Alzheimer's disease.
How similar studies have performed: Previous research has shown success in developing small molecules for similar targets in Alzheimer's disease, indicating a promising approach.
Where this research is happening
Atlanta, United States
- Emory University — Atlanta, United States (Active)
Researchers
- Principal investigator: Levey, Allan I — Emory University
- Study coordinator: Levey, Allan I
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.